OxyContin® abuse and overdose

Postgraduate Medicine

Volumn 121, Issue 2, 2009, Pages 163-167

  Aquina, Christopher T ^a   Marques Baptista, Andreia ^a   Bridgeman, Patrick ^b   Merlin, Mark A ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

Addiction; Opioid; Overdose; OxyContin ; Substance abuse

Indexed keywords

NALOXONE; OPIATE ANTAGONIST; OXYCODONE; NARCOTIC ANALGESIC AGENT;

ARTICLE; BRADYCARDIA; DIFFERENTIAL DIAGNOSIS; DRUG ABUSE; DRUG MEGADOSE; DRUG OVERDOSE; HUMAN; HYPOTENSION; HYPOTHERMIA; LOW DRUG DOSE; MENTAL HEALTH; MIOSIS; OXYGEN THERAPY; PAIN; RESPIRATORY TRACT DISEASE; SYMPTOM; DELAYED RELEASE FORMULATION; INTOXICATION; OPIATE ADDICTION; REVIEW;

ANALGESICS, OPIOID; DELAYED-ACTION PREPARATIONS; DIAGNOSIS, DIFFERENTIAL; HUMANS; OPIOID-RELATED DISORDERS; OVERDOSE; OXYCODONE;

EID: 64849113540     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2009.03.1988     Document Type: Article

References (31)

1. OxyContin [package insert]. Stamford, CT: Purdue Pharma, LP; 2007. http://www.pharma.com/html/our-products/our-products.htm. Accessed September 12, 2008.
2. Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician. 2008;11(2 suppl):S133-S153.
3. Gossop M, Griffiths P, Powis B, Strang J. Cocaine: patterns of use, route of administation, and severity of dependence. Br J Psychiatry. 1994;164(5):660-664. (Pubitemid 24161265)
4. Marsch LA, Bickel WF, Badger WJ, et al. Effects of infusion rate of intravenously administered morphine on physiological, pscyhomotor, and self-reported measures in humans. J Pharmacol Exp Ther. 2001;299(3):1056-1065. (Pubitemid 33104978)
5. Oldendorf WH. Some relationships between addiction and drug delivery to the brain. NIDA Res Monogr. 1992;120:13-25. (Pubitemid 23095632)
6. Roset PN, Farré M, de la Torre R, et al. Modulation of rate of onset and intensity of drug effects reduces abuse potential in healthy males. Drug Alcohol Depend. 2001;64(3):285-298. (Pubitemid 32973872)
7. Cicero TJ, Inciardi JA, Muñoz A. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004. J Pain. 2005;6(10):662-672.
8. Roche T. The potent perils of a miracle drug. Time. 2001;157(1):47.
9. Jayawant SS, Balkrishnan R. The controversy surrounding OxyContin abuse: issues and solutions. Ther Clin Risk Manag. 2005;1(2):77-82.
10. Suffett WL. OxyContin abuse. J Ky Med Assoc. 2001;99(2):72.
11. Tunnell KD. The OxyContin epidemic and crime panic in rural Kentucky. Contemporary Drug Problems. 2005;32(2):225. (Pubitemid 41148450)
12. US Department of Health and Human Services. CSAT Advisory. OxyContin: prescription drug abuse. April 1, 2001.
13. Katz DA, Hays LR. Adolescent OxyContin Abuse. J Am Acad Child Adolesc Psychiatry. 2004;43(2):231-234.
14. US Department of Justice, Drug Enforcement Administration. Office of Diversion Control, Drugs and chemicals of concern: summary of medical examiner reports on oxycodone-related deaths. http://www.deadiversion.usdoj.gov/drugs- concern/oxycodone/oxycontin7.htm. Published July 21, 2008. Accessed October 1, 2008.
15. Substance Abuse and Mental Health Services Administration. Drug Abuse Warning Network, 2005: national estimates of drug-related emergency department visits. DAWN Scries D-29, 2007. Rockville, MD: SAMHSA; 2007.
16. Cone EJ, Frant RV, Rohay JM, et al. Oxycodone involvement in drug abuse deaths: a DAWN-based classification scheme applied to an oxycodone postmortem database containing over 1000 cases. J Anal Toxicol. 2003;27(2):57-67. (Pubitemid 36292977)
17. Drummer OH, Surkamem ML, Phelan M, Cordner SM. A study of deaths involving oxycodone. J Forensic Sci. 1994;39(4):1069-1075.
18. Substance Abuse and Mental Health Services Administration. The DAWN Report: oxycodone, hydrocodone, and polydrug use, 2002. Rockville, MD: SAMHSA; July 2004.
19. Arnold C. Teen abuse of painkiller OxyContin on the rise. All Things Considered. National Public Radio. 2005. http://www.npr.org/templates/story/ story.php?storyId=5061674. Accessed October 1, 2008.
20. Goldfrank L, Flomenbaum NE, Lewin N, et al. Goldfrank's Toxicologic Emergencies. 8th cd. New York, NY: The McGraw-Hill Companies, Inc; 2006.
21. Schneir AB, Vadeboncoeur TF, Offerman SR, et al. Massive OxyContin ingestion refractory to naloxone therapy. Ann Emerg Med. 2002;40(4):425-428.
22. Weil JV, McCullough RE, Kline JS, Sodal IE. Diminished ventilatory response to hypoxia and hypereapnia after morphine in normal man. N Engl J Med. 1975;292(21):1103-1106.
23. Osler W. Oedema of left lung-Morphia poisoning. Montreal General Hospital Reports. Vol 1. Montreal, Canada: Dawson Bros Publishers; 1880:291-293.
24. Ward JM, McGrath RL, Weil JV. Effects of morphine on the peripheral vascular response to sympathetic stimulation. Am J Cardiol. 1972;29(5):659-666.
25. Fahmy NR, Sunder N, Soter NA. Role of histamine in the hemodynamic and plasma catecholamine responses to morphine. Clin Pharmacol Ther. 1983;33(5):615-620.
26. Barke KE, Hough LB. Opiates, mast cells and histamine release. Life Sci. 1993;53(18):1391-1399. (Pubitemid 23288945)
27. Lee HK, Wang SC. Mechanism of morphine-induced miosis in the dog. J Pharmacol Exp Ther. 1975;192(2):415-431.
28. Greene D. Total necrosis of the intranasal structures and soft palate as a result of nasal inhalation of crushed OxyContin. Ear Nose Throat Journal. 2005;84(8):512, 514, 516.
29. Davis MP, Varga J, Dickerson D, et al. Normal release and controlled release oxycodone: pharmacokinetics, pharmacodynamics and controversy. Support Care Cancer. 2003;11(2):84-92. (Pubitemid 36733817)
30. Bracken MB, Shepard MJ, Collins WF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med. 1990;322(20):1405-1411. (Pubitemid 20152525)
31. Buajordet I, Naess AC, Jacobsen D, Brors D. Adverse events after naloxone treatment of episodes of suspected acute opioid overdose. Eur J Emerg Med. 2004;11(1):19-23.